Lactulose mediates suppression of dextran sodium sulfate-induced colon inflammation by increasing hydrogen production

Digestive Diseases and Sciences

Volumn 58, Issue 6, 2013, Pages 1560-1568

  Chen, Xiao ^a   Zhai, Xiao ^a   Shi, Jiazi ^b   Liu, Wen Wu ^b   Tao, Hengyi ^b   Sun, Xuejun ^b   Kang, Zhimin ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antioxidant; Hydrogen; Lactulose; Oxidative stress; Ulcerative colitis

Indexed keywords

CEFRADINE; DEXTRAN SULFATE; INTERLEUKIN 1BETA; LACTULOSE; MALONALDEHYDE; METRONIDAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; COLON INJURY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; HISTOPATHOLOGY; HYDROGEN BREATH TEST; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECTUM HEMORRHAGE; ULCERATIVE COLITIS; WEIGHT CHANGE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; BREATH TESTS; COLITIS; COLON; DEXTRAN SULFATE; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL AGENTS; HYDROGEN; LACTULOSE; MALE; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; RANDOM ALLOCATION;

EID: 84879504879     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2563-7     Document Type: Article

References (38)

1. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33:6S-15S.
2. Suematsu M, Suzuki M, Kitahora T, et al. Increased respiratory burst of leukocytes in inflammatory bowel diseases - the analysis of free radical generation by using chemiluminescence probe. J Clin Lab Immunol. 1987;24:125-128.
3. Karp SM, Koch TR. Oxidative stress and antioxidants in inflammatory bowel disease. Dis Mon. 2006;52:199-207.
4. Keshavarzian A, Morgan G, Sedghi S, Gordon JH, Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut. 1990;31:786-790.
5. Neilly PJ, Gardiner KR, Rowlands BJ. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut. 1996;38:475.
6. Buffinton GD, Doe WF. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic Biol Med. 1995;19:911-918.
7. Oz HS, Chen TS, McClain CJ, de Villiers WJ. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem. 2005;16:297-304.
8. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13:688-694.
9. Huang CS, Kawamura T, Toyoda Y, Nakao A. Recent advances in hydrogen research as a therapeutic medical gas. Free Radic Res. 2010;44:971-982.
10. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (dss) is characterized by th1 and th2 cytokines. Clin Exp Immunol. 1998;114:385-391.
11. Kajiya M, Silva MJ, Sato K, Ouhara K, Kawai T. Hydrogen mediates suppression of colon inflammation induced by dextran sodium sulfate. Biochem Biophys Res Commun. 2009;386:11-15.
12. Florent C, Flourie B, Leblond A, Rautureau M, Bernier JJ, Rambaud JC. Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study). J Clin Invest. 1985;75:608-613.
13. Kim YJ, Kim EH, Hahm KB. Oxidative stress in inflammation-based gastrointestinal tract diseases: challenges and opportunities. J Gastroenterol Hepatol. 2012;27:1004-1010.
14. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299-315.
15. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
16. Damiani CR, Benetton CA, Stoffel C, et al. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol. 2007;22:1846-1851.
17. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis. 2003;24:353-362.
18. Hayashida K, Sano M, Ohsawa I, et al. Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun. 2008;373:30-35.
19. Fukuda K, Asoh S, Ishikawa M, Yamamoto Y, Ohsawa I, Ohta S. Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. Biochem Biophys Res Commun. 2007;361:670-674.
20. Buchholz BM, Kaczorowski DJ, Sugimoto R, et al. Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. Am J Transplant. 2008;8:2015-2024.
21. Gharib B, Hanna S, Abdallahi OM, Lepidi H, Gardette B, De Reggi M. Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation. C R Acad Sci III. 2001;324:719-724.
22. Chen H, Sun YP, Li Y, et al. Hydrogen-rich saline ameliorates the severity of l-arginine-induced acute pancreatitis in rats. Biochem Biophys Res Commun. 2010;393:308-313.
23. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968-1976.
24. Voskuijl W, de Lorijn F, Verwijs W, et al. Peg 3350 (transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut. 2004;53:1590-1594.
25. Chen X, Zuo Q, Hai Y, Sun XJ. Lactulose: an indirect antioxidant ameliorating inflammatory bowel disease by increasing hydrogen production. Med Hypotheses. 2011;76:325-327.
26. Rhodes JM, Middleton P, Jewell DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol. 1979;14:333-336.
27. Sen S, Dear KL, King TS, Elia M, Hunter JO. Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14:753-756.
28. Hentschel U, Dobrindt U, Steinert M. Commensal bacteria make a difference. Trends Microbiol. 2003;11:148-150.
29. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115-1118.
30. Panesar PS, Kumari S. Lactulose: production, purification and potential applications. Biotechnol Adv. 2011;29:940-948.
31. Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis. 2009;15:454-462.
32. Kajiya M, Sato K, Silva MJ, et al. Hydrogen from intestinal bacteria is protective for concanavalin a-induced hepatitis. Biochem Biophys Res Commun. 2009;386:316-321.
33. Huchzermeyer H, Schumann C. Lactulose - a multifaceted substance. Z Gastroenterol. 1997;35:945-955.
34. Hoffmann K, Mossell DAA, Korus W, van de Kamer JH. Investigations on the mode of action of lactulose in the human intestine. Klin Wochenschr. 1964;42:126-130.
35. Schumann C. Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr. 2002;41:I17-I25.
36. Xie K, Yu Y, Zhang Z, et al. Hydrogen gas improves survival rate and organ damage in zymosan-induced generalized inflammation model. Shock. 2010;34:495-501.
37. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol. 2010;16:3347-3357.
38. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2010;51:1062-1069. Medical University